Published in Cardiol Res Pract on October 24, 2013
Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction | NCT01516346
If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure | NCT00757055
Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?". World J Cardiol (2015) 0.76
Exploring Guidelines for Classification of Major Heart Failure Subtypes by Using Machine Learning. Clin Med Insights Cardiol (2015) 0.76
Hemodynamic monitoring in heart failure and pulmonary hypertension: From analog tracings to the digital age. World J Transplant (2016) 0.75
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med (2006) 17.13
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med (2004) 8.12
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42
Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation (2011) 5.06
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol (2013) 5.04
Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA (2012) 4.57
The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J (2006) 4.10
Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA (2002) 4.06
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J (2010) 3.62
Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation (2008) 3.56
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34
Aortic stiffness is increased in hypertrophic cardiomyopathy with myocardial fibrosis: novel insights in vascular function from magnetic resonance imaging. J Am Coll Cardiol (2009) 3.19
Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol (2011) 3.19
Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol (2011) 3.13
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J (2011) 2.97
PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail (2010) 2.82
Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol (2009) 2.68
Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol (2012) 2.56
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation (2008) 2.51
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation (2002) 2.41
Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail (2010) 2.35
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J (2013) 2.32
Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail (2010) 2.30
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol (2009) 2.21
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol (2012) 2.19
Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation (2012) 2.14
Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res (1993) 2.04
Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation (2012) 2.03
Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation (2005) 1.97
Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction >35%: a PROSPECT trial substudy. Eur J Heart Fail (2010) 1.95
Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail (2009) 1.84
Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation (2008) 1.83
Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation (2010) 1.72
Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension (2010) 1.69
Cardiovascular effects of 1 year of progressive endurance exercise training in patients with heart failure with preserved ejection fraction. Am Heart J (2012) 1.68
Systolic and diastolic dyssynchrony in patients with diastolic heart failure and the effect of medical therapy. J Am Coll Cardiol (2006) 1.68
Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol (2009) 1.67
Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension (2010) 1.64
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Nutritional vitamin D in dialysis patients: what to D-iscern? Nephrol Dial Transplant (2011) 1.49
Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA (2008) 1.40
Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res (2012) 1.39
Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol (1990) 1.34
Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol (2013) 1.34
Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep (2010) 1.33
Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail (2004) 1.26
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J (2012) 1.24
Age disparities in heart failure research. JAMA (2010) 1.23
Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol (2011) 1.17
Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail (2011) 1.16
Cardiac resynchronization therapy for the causal treatment of heart failure with preserved ejection fraction: insight from a pressure-volume loop analysis. Eur J Heart Fail (2010) 1.11
Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail (2011) 1.10
Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail (2012) 1.07
Left ventricular torsion and strain patterns in heart failure with normal ejection fraction are similar to age-related changes. Eur J Echocardiogr (2009) 1.07
Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep (2012) 1.05
Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clin Cardiol (2011) 1.03
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail (2013) 1.02
Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail (2012) 1.02
Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade. Hypertension (2012) 0.99
Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol (2011) 0.98
How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail (2013) 0.98
Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J (2012) 0.96
Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. Am J Cardiol (2008) 0.96
Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction. J Am Coll Cardiol (2012) 0.94
Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. J Am Coll Cardiol (2010) 0.92
Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. Am J Med (2013) 0.92
The restoration of chronotropic competence in heart failure patients with normal ejection fraction (RESET) study: rationale and design. J Card Fail (2009) 0.91
Diagnosing heart failure with preserved ejection fraction. Expert Opin Med Diagn (2013) 0.88
Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. Hypertension (2009) 0.86
Understanding results of trials in heart failure with preserved ejection fraction: remembering forgotten lessons and enduring principles. J Am Coll Cardiol (2011) 0.86
Myocardial ischemia in patients with diastolic dysfunction and heart failure. Curr Cardiol Rep (2010) 0.86
Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis (2005) 0.85
Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail (2010) 0.85
Statin therapy in patients with diastolic heart failure. Clin Cardiol (2010) 0.84
Heart failure therapy: what should clinicians believe? JAMA (2012) 0.83
The impact of extra cardiac comorbidities on pressure volume relations in heart failure and preserved ejection fraction. J Card Fail (2011) 0.83
Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study. Eur J Heart Fail (2010) 0.81
Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract (2002) 0.81
Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis. J Card Fail (2008) 0.80
Exercise training in patients with heart failure and preserved ejection fraction: findings awaiting discovery. J Am Coll Cardiol (2013) 0.79
Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel? Eur J Heart Fail (2012) 0.78
Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. Eur Heart J (2006) 0.77
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Genetics and beyond--the transcriptome of human monocytes and disease susceptibility. PLoS One (2010) 7.48
Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med (2009) 6.62
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation (2008) 5.20
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet (2009) 3.81
Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation (2007) 3.76
Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation (2002) 3.20
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation (2005) 3.02
A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature (2010) 2.88
Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA (2011) 2.61
Protective role of angiopoietin-1 in endotoxic shock. Circulation (2004) 2.53
Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24
Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res (2005) 2.24
Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction. Circulation (2008) 2.20
Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome. Clin Chem (2011) 2.14
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost (2004) 2.09
Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. Int J Cardiol (2012) 2.02
Severe intraprocedural complications after transcatheter aortic valve implantation: calling for a heart team approach. Eur J Cardiothorac Surg (2013) 2.01
How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J (2012) 2.00
Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. Circulation (2011) 1.96
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet (2011) 1.92
High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J (2013) 1.85
Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J (2008) 1.82
Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. Circ Cardiovasc Genet (2009) 1.81
Cardiac deletion of the Coxsackievirus-adenovirus receptor abolishes Coxsackievirus B3 infection and prevents myocarditis in vivo. J Am Coll Cardiol (2009) 1.81
Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J (2010) 1.80
Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension (2008) 1.78
Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol (2010) 1.75
Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation (2009) 1.71
A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J (2011) 1.67
Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. Diabetes Care (2010) 1.66
Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J (2005) 1.65
A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet (2011) 1.63
Left ventricular dysfunction induced by nonsevere idiopathic pulmonary arterial hypertension: a pressure-volume relationship study. Am J Respir Crit Care Med (2012) 1.59
Predictors and outcomes after transcatheter aortic valve implantation using different approaches according to the valve academic research consortium definitions. Catheter Cardiovasc Interv (2013) 1.58
Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J (2004) 1.58
Development of diastolic heart failure in a 6-year follow-up study in patients after acute myocarditis. Heart (2010) 1.57
The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J (2008) 1.57
Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One (2010) 1.53
Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J (2011) 1.52
Noninvasive vascular function measurement in the community: cross-sectional relations and comparison of methods. Circ Cardiovasc Imaging (2011) 1.52
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J (2013) 1.46
Low immunogenicity of endothelial derivatives from rat embryonic stem cell-like cells. Cell Res (2009) 1.46
The inflammatory hypothesis: any progress in risk stratification and therapeutic targets? Circulation (2006) 1.45
The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J (2005) 1.44
Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol (2011) 1.41
Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans. PLoS Genet (2011) 1.40
Somatic symptoms in patients with coronary heart disease: prevalence, risk factors, and quality of life. JAMA Intern Med (2013) 1.40
Impact of infectious burden on progression of carotid atherosclerosis. Stroke (2002) 1.40
Kidney injury and mortality after transcatheter aortic valve implantation in a routine clinical cohort. Catheter Cardiovasc Interv (2014) 1.39
Transseptal and transmitral Parachute® implantation in conjunction with "MitraClipping". EuroIntervention (2015) 1.38
Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines. Am J Cardiol (2003) 1.34
Analyzing illumina gene expression microarray data from different tissues: methodological aspects of data analysis in the metaxpress consortium. PLoS One (2012) 1.31
Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol (2008) 1.31
Discovery and fine mapping of serum protein loci through transethnic meta-analysis. Am J Hum Genet (2012) 1.29
Truncation of titin's elastic PEVK region leads to cardiomyopathy with diastolic dysfunction. Circ Res (2009) 1.29
Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail (2010) 1.27
Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ Cardiovasc Genet (2011) 1.26
Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2007) 1.22
Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail (2010) 1.22
Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res (2009) 1.21
Statistical colocalization of monocyte gene expression and genetic risk variants for type 1 diabetes. Hum Mol Genet (2012) 1.20
Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) (2006) 1.20
The relation of genetic and environmental factors to systemic inflammatory biomarker concentrations. Circ Cardiovasc Genet (2009) 1.19
Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clin Res Cardiol (2013) 1.16
Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol (2002) 1.15
Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail (2013) 1.14
High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol (2003) 1.13
Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J Mol Med (Berl) (2008) 1.13
Glutathione peroxidase-1 activity, atherosclerotic burden, and cardiovascular prognosis. Am J Cardiol (2007) 1.12
Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. Eur J Heart Fail (2008) 1.10
Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet (2004) 1.08
Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J (2004) 1.08
Oxidative stress in cardiovascular disease: successful translation from bench to bedside? Circulation (2007) 1.07
Global strain rate imaging for the estimation of diastolic function in HFNEF compared with pressure-volume loop analysis. Eur J Echocardiogr (2010) 1.06
Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction: results from the AtheroGene study. J Am Coll Cardiol (2005) 1.05
Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis (2008) 1.04
Development of a risk score for outcome after transcatheter aortic valve implantation. Clin Res Cardiol (2014) 1.04
Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J (2009) 1.04
Genome-wide haplotype analysis of cis expression quantitative trait loci in monocytes. PLoS Genet (2013) 1.03
TRIF is a critical survival factor in viral cardiomyopathy. J Immunol (2011) 1.03
Genomewide association studies in cardiovascular disease--an update 2011. Clin Chem (2011) 1.03
Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. Circulation (2011) 1.03
Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis (2006) 1.03
GUESS-ing polygenic associations with multiple phenotypes using a GPU-based evolutionary stochastic search algorithm. PLoS Genet (2013) 1.03
Edwards Sapien XT valve placement as treatment option for aortic regurgitation after transfemoral CoreValve implantation: a multicenter experience. Clin Res Cardiol (2013) 1.03
Activation of mitochondrial energy metabolism protects against cardiac failure. Aging (Albany NY) (2010) 1.02
Bayesian detection of expression quantitative trait loci hot spots. Genetics (2011) 1.00
Transcatheter mitral valve-in-valve implantation in patients with degenerated bioprostheses. JACC Cardiovasc Interv (2012) 1.00
Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation (2009) 1.00